Method of inhibiting DYRK1B

US10633369B2 · kind B2 · utility

Assignee

• 4SC AG · DE

Inventors

• Fritz Aberger · Salzburg, AT
• Wolfgang Gruber · Bischofswerda, DE
• Johann Leban · Planegg, DE
• Hella KOHLHOF · Munich, DE
• Daniel VITT · Germering, DE
• Roland BAUMGARTNER · Birkenfeld, DE

Key dates

• Filing date: Mar 8, 2018
• Grant date: Apr 28, 2020
• Expiry date: Mar 8, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.